In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Decibel Therapeutics, Inc.

Latest From Decibel Therapeutics, Inc.

Regeneron Aiming To Be A Cell And Gene Medicine ‘Powerhouse’

Increased R&D spending, program acquisitions and a soaring headcount – Regeneron has seen significant growth over the past 5 years. The company is focused on marrying its antibody technologies with its expanding cell and gene therapy pipeline. 

Regenerative Medicine Innovation

Regeneron Gene Therapy Reaches New Heights In Restoring Hearing

The US biotech’s DB-OTO has made headlines worldwide after a baby with profound genetic deafness experienced improved hearing to normal levels within 24 weeks after a single intracochlear injection.

Ear Gene Therapy

Dupixent COPD Approval Could Be Delayed, Regeneron Cautions

The US Food and Drug Administration has requested additional efficacy information on the supplemental filing in the potentially large new indication.

Immune Disorders Inflammation

Regeneron Strikes A CHORD With Deafness Gene Therapy

A very early success with a gene therapy for a rare form of deafness puts Regeneron ahead of Lilly and Sensorion.

Gene Therapy Ear, Nose & Throat
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics